Kerala Ayurveda Quarterly Results for Trading Insights
In Sept 2025, Kerala Ayurveda (KERALAYUR) reported revenue ₹37 Cr and net profit ₹-6 Cr — revenue +19.4% YoY. For annual financials, live price and key ratios, visit KERALAYUR stock live price.
KERALAYUR Quarterly Results — Revenue, Profit & EPS Highlights
Kerala Ayurveda latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with KERALAYUR intrinsic value calculation to assess whether the stock is under or overvalued.
- Revenue of ₹37 Cr in Sept 2025 (+15.6% vs Mar 2025, +19.4% vs Sept 2024)
- Net Profit of ₹-6 Cr in Sept 2025 (+60.0% vs Mar 2025, -250.0% vs Sept 2024)
- EBITDA of ₹-3 Cr in Sept 2025 (+66.7% vs Mar 2025)
- Operating Margin of -14.0% in Sept 2025 (+18.0pp vs Mar 2025)
- Earnings Per Share of ₹-7.23 in Sept 2025 (+47.1% vs Mar 2025)
Kerala Ayurveda Quarterly Results — Revenue, EBITDA, Net Profit & EPS
KERALAYUR quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 37 | 32 | 38 | 34 | 31 | 15.6% | 19.4% |
| Net Profit (₹ Cr) | -6 | -15 | 2 | -5 | 4 | - | - |
| EBITDA (₹ Cr) | -3 | -9 | 5 | 0 | 6 | - | - |
| EPS (₹) | -7.23 | -13.68 | 1.92 | -3.69 | 3.10 | - | - |
| Operating Margin (%) | -14.0% | -32.0% | -15.0% | -5.0% | 18.0% | - | - |
KERALAYUR Share Price Trend — 1-Year Movement Across Quarterly Results
Kerala Ayurveda 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse KERALAYUR ownership pattern to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
KERALAYUR vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Kerala Ayurveda latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹415,924.72 Cr | 1778.7 | 14,875 | 3,125 | +10.8% | - | 21.0% | 136.8 |
|
Divis Laboratories
Sept 2025 |
₹171,625.44 Cr | 6534.0 | 2,860 | 689 | +7.1% | - | 24.1% | 251.6 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹139,344.76 Cr | 4231.5 | 3,219 | 591 | +11.3% | - | 18.4% | 241.2 |
|
Dr Reddys Laborator…
Sept 2025 |
₹109,930.83 Cr | 1329.8 | 9,135 | 1,337 | +1.1% | - | 14.6% | 82.2 |
|
Lupin
Sept 2025 |
₹104,941.69 Cr | 2311.4 | 6,921 | 1,485 | +23.2% | - | 21.5% | 71.4 |
All amounts in ₹ Crores